• Novartis broke ground on a 46,000-square-foot radioligand therapy manufacturing site in Denton, Texas, extending its US production footprint for highly personalized cancer treatments.
• Facility expected to start operations in 2028, adding jobs in bioengineering, advanced manufacturing, quality, and operations.
• Project marks latest step in a USD 23 billion, five-year push to expand US research and manufacturing, targeting domestic production of key medicines for US patients.
• Denton site becomes fifth US radioligand therapy facility, adding capacity alongside existing sites in New Jersey, Indiana, and California, with another new site planned in Florida.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605070900OMX_____CNEWS_EN_GNW1001180609_en) on May 07, 2026, and is solely responsible for the information contained therein.